Know Cancer

forgot password

18 Years
67 Years
Not Enrolling
Acute Myeloid Leukemia

Thank you

Trial Information

BU levels are largely unpredictable, patients are often exposed to the toxic effects of
inappropriate drug regimens before dose modifications can be made. Although the importance
of TDM cannot be over emphasized, it entails trial and error and does not allow for pre-
treatment dose optimization. This study, which provides an integration of genetic and
pharmacokinetic data analysis of patients preconditioned for HSCT with high dose oral BU,
aims to define biomarkers predictive of poor BU metabolism and clearance to prevent
potential drug toxicity.This study is not an interventional study, only investigates the GST
and MDR-1 genes in correlation with the "routine" Busulfan AUC done during the preparative
regimen in HSCT for AML patients.

Inclusion Criteria:

- Acute Myeloid Leukemia who are clinically selected for HSCT according to known

Exclusion Criteria:

- Unable to give informed consent

Type of Study:


Study Design:

Time Perspective: Prospective

Outcome Measure:

If GST and ABCB1 genes modify busulfan pharmacokinetics in AML patients who will be transplanted

Outcome Description:

If individuals diagnosed with AML carrying the GSTP1 variant allele rs1695 (heterozygotes) are at risk of developing supra-therapeutic BU AUC due to lower BU clearance, and if combined polymorphisms in GSTM1 and ABCB1 (3435 or 2677) are associated with BU clearance rates and AUC.

Outcome Time Frame:

end of BMT transplantation

Safety Issue:



Israel: Ministry of Health

Study ID:




Start Date:

January 2010

Completion Date:

December 2011

Related Keywords:

  • Acute Myeloid Leukemia
  • Pharmacokinetics
  • Busulfan
  • Polymorphism
  • GST
  • MDR-1(p-Glycoprotein)
  • Acute Myeloid Leukemia adult patients
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid